Activity of acyclic halogenated tubercidin analogs against human cytomegalovirus and in uninfected cells by Nassiri, M. Reza et al.
Antiviral Research, 16 (1991) 135-150 




Activity of acyclic halogenated tubercidin analogs 
against human cytomegalovirus and in 
uninfected cells 
M. Reza Nassiri ~, Steven R. Turk ~, Gary M. Birch ~, Lisa A. Coleman ~, 
Jerry L. Hudson 2, Jeffrey S. Pudlo ~, Leroy B. Townsend 3 and 
John C. Drach ~ 
~Department of Biologic and Materials Sciences, School of Dentistry, 3Interdepartmental Program in 
Medicinal Chemistry, College of Pharmacy, The University of Michigan, Ann Arbor, Michigan and 
2Beckton Dickenson Immunocytometry Systems, San Jose, California, U.S.A. 
(Received 7 May 1990; accepted 21 August 1990) 
Summary 
Novel acyclic halogenated tubercidins (4-amino-5-halo-7-[(2-hydroxyethoxy)- 
methyl]pyrrolo[2,3-d]pyrimidines) were examined for their ability to inhibit 
human cytomegalovirus (HCMV) in yield reduction assays. 5-Bromo acyclic tub- 
ercidin (compound 102) was a more potent inhibitor of virus replication than the 
chloro- and iodo-substituted analogs (compounds 100 and 104). At a 100/zM con- 
centration, the bromo and chloro compounds were more potent than acyclovir but 
not ganciclovir. Virus titers were reduced more than 99% by compounds 102 and 
104 whereas compound 100 and the equally potent acyclovir reduced titers by only 
90%. Quantitation of viral DNA by DNA hybridization demonstrated strong inhi- 
bition of HCMV DNA synthesis by these compounds. The most potent inhibitor, 
compound 102, had a 50% inhibitory (150) concentration (1.6/tM) comparable to 
that of ganciclovir (1.8/.tM). Cytotoxicity in uninfected human cells was evaluated 
and revealed the following: cell growth rates slowed markedly in the presence of 
10/zM compound 102 whereas the same concentration of compounds 100 and 104 
led to only a slight prolongation of population doubling time; these compounds 
inhibited cellular DNA synthesis but not RNA or protein synthesis, as measured by 
incorporation of radiolabeled precursors into acid-precipitable macromolecules; 
flow cytometry indicated that compound 102 was a mid-S phase blocker, and ade- 
nosine antagonized the inhibition of [3H]dThd incorporation by compound 102. 
Correspondence to: J.C. Drach, University of Michigan, School of Dentistry, Ann Arbor, MI 48109- 
1078, U.S.A. 
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Together, these results demonstrate that compound 102 is a potent and selective 
inhibitor of viral and cellular DNA synthesis and that acyclic halogenated pyrrolo- 
pyrimidine nucleosides may have therapeutic potential. 
Cytomegalovirus; Herpes; 7-Deaza adenosine; Pyrrolopyrimidine; Nucleoside 
Introduction 
Immunosuppressed individuals are susceptible to infection by human cytomega- 
lovirus (HCMV); consequently this opportunistic virus is the causative agent of 
morbidity and mortality in AIDS patients (Jacobson and Mills, 1988; Klatt and Shi- 
bata, 1988; Niedt and Schinella, 1985) and other immunocompromised individuals 
such as bone marrow transplant recipients and renal allograft patients (Betts and 
Hanshaw, 1977; Bombi et al., 1987; Glen, 1981). Neonates also are susceptible to 
severe HCMV infections (Mostoufi-Zadeh et al., 1984). Thus, there is an immedi- 
ate need for non-toxic drugs to treat infections caused by this virus. Although a 
number of compounds are active against HCMV in vitro (Colacino and Lopez, 
1983; Field et al., 1983; Mar et al., 1984; Plotkin et al., 1985), only the acyclic 
nucleosides ganciclovir (DHPG) and acyclovir and the pyrophosphate analog fos- 
carnet are sufficiently promising for clinical use against certain HCMV infections 
(Collaborative DHPG Treatment Study Group, 1986; Jacobson and Mills, 1988; 
Meyers et al., 1988; Morris, 1988; Rosecan et al., 1986; Shepp et al., 1985; Skol- 
nick and Hirsch, 1988). Nonetheless, these compounds suffer from disadvantages 
of low potency (Meyers et al., 1988), lack of efficacy in certain circumstances 
(O'Donnell et al., 1987; Shepp et al., 1985), and cytotoxic manifestations in some 
therapeutic regimens (Morris, 1988; Skolnik and Hirsch, 1988). Thus, there is yet a 
substantial need to discover more potent and safer drugs to treat HCMV infections. 
In our search for novel and more efficacious drugs to treat infections caused by 
herpesviruses, particularly HCMV, we have found that pyrrolopyrimidine nucleo- 
sides are potent inhibitors of HCMV in vitro. Particularly, certain deoxyribosyl and 
arabinosyl pyrrold[2,3-d]pyrimidines have selective antiviral activity against this 
virus (Turk et al., 1987b). Of these fraudulent nucleosides, ara-sangivamycin, ara- 
toyocamycin, and 2'-deoxysangivamycin had the best antiviral selectivity. Based 
upon this lead, our group designed and synthesized acyclic analogs of tubercidin, 
toyocamycin, and sangivamycin (Gupta et al., 1989a,b; Pudlo et al., 1988, 1990; 
Saxena et al., 1988) with the objective of reducing cytotoxicity and retaining anti- 
viral activity. Five-halogen substituted analogs of tubercidin have shown particu- 
larly good activity against HCMV in early investigations (Pudlo et al., 1988, 1990). 
In the present work, we have expanded the antiviral assessment of some of these 
novel halogenated acyclic tubercidin analogs against HCMV and have explored the 
cellular and molecular basis by which these compounds act. 
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Materials and Methods 
Chemicals  
The acyclic tubercidin analogs referred to herein as compounds 080, 100, 102, 
and 104 were synthesized in the laboratory of one of us (LBT) as described pre- 
viously (Saxena et al., 1988; Pudlo et al., 1988). They are, respectively, 4-amino-7- 
[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidine and its 5-chloro, 5-bromo, 
and 5-iodo derivatives (Fig. 1). Acyclovir was provided by Burroughs Wellcome 
Co., Research Triangle Park, NC. Ganciclovir was obtained from Syntex Laborato- 
ries, Inc., Palo Alto, CA, through the courtesy of Dr. T. Matthews. [Methyl-3H]thy - 
midine (40 Ci/mol), [5-3H]uridine (22 Ci/mmol), 3H-L-amino acid mixture (273 
m C i / m g ) ,  [32p]H3PO 4 (Pi; 100 mCi/ml), and [o~-32p]dCTP (3048 Ci/mmol) were 
purchased from ICN Radiochemicals Inc., Irvine, CA. Fetal bovine serum was pur- 
chased from Hyclone Laboratories, Inc., Logan, UT. Propidium diiodide was pur- 
chased from Calbiochem Corp., La Jolla, CA. RNase 1-A was purchased from 
Sigma Chemical Co., St. Louis, MO. 
Cells and  virus 
KB cells, an established human cell line derived from an epidermal oral carci- 
noma, were routinely grown in minimal essential medium (MEM) with Hanks salts 
[MEM(H)] supplemented with 5% fetal bovine serum. Diploid cell cultures of 
human foreskin fibroblasts (HFF) were grown in MEM with Earle salts [MEM(E)] 
supplemented with 10% fetal bovine serum. Cells were passaged by conventional 
procedures by using 0.05% trypsin and 0.02% EDTA in a HEPES (N-2-hydroxy- 
ethylpiperazine-N'-2-ethanesulfonic acid)-buffered salt solution [HBS (Shipman, 
1969)]. To increase the likelihood of detecting bacterial or mixed bacterial and 
mycoplasmal contamination, antibiotics were never used in the routine passage of 
cells (Hayflick, 1973). Cell lines were screened periodically and were mycoplasma 
free. 
The plaque-purified isolate (P0) of the Towne strain of HCMV was a gift of Dr. 
Mark Stinski, University of Iowa. The preparation of HCMV stocks and the 
titration of virus were performed as described previously (Turk et al., 1987b). 
HO ~, , , , .0~  
Fig. 1. Structures of the acyclic tubercidin analogs 080 (X=H), 100 (X=C1), 102 (X=Br), and 104 (X=I). 
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Assay for antiviral activity 
The effect of the selected compounds on the replication of HCMV was measured 
using a titer (yield) reduction assay as we reported previously (Turk et al., 1987b). 
Briefly, monolayer cultures of HFF cells were infected at a multiplicity of infection 
of 0.5 PFU per cell and incubated in the presence of test compounds for 7 to 10 
days. Following three cycles of freezing at -76°C and thawing at 37°C, the 
resulting lysates were diluted and the amount of infectious virus was quantitated on 
new cultures of HFF cells. 
Quantification of viral DNA 
Viral DNA synthesized in HCMV-infected cells was quantitated by DNA-DNA 
dot blot hybridization procedures as detailed previously (Turk et al., 1987b). 
Briefly, cultures were infected with 0.5 PFU per cell and incubated with test com- 
pounds for seven days. Cultures were harvested and filtered through a Gene Screen 
membrane (New England Nuclear Corp., Boston, MA). The membrane was hybrid- 
ized with an E. coli plasmid probe (pACYC-184, obtained through the courtesy of 
Dr. Stinski) containing a fragment of the HCMV genome which had been nick 
translated with [32p]dCTP. The hybridized label was quantitated using a Beckman 
model LS 8100 liquid scintillation spectrometer. 
Uptake of labeled precursors 
Activity of compounds in uninfected KB cells as well as in HFF cells was deter- 
mined by measuring the effects of compounds on cellular DNA, RNA and protein 
synthesis essentially as described previously (Turk et al., 1987b; Birch et al., 
1989). Briefly, monolayer cultures were incubated for 18 to 24 h in the presence of 
test compounds and either [3H]dThd, [3H]Urd, 3H-amino acids, or [32p]Pi at a final 
concentration of 2 to 3//Ci/ml of labeled precursor. [3H]dThd and [3H]Urd were 
diluted with unlabeled nucleoside to give a final concentration of 3 to 6 / tM (nonin- 
hibitory during the course of the assay). At the end of the incubation period, cells 
were harvested onto filter paper using a Skatron cell harvester (Skatron, Inc., Ster- 
ling, VA) and washed free of unincorporated label with sequential washes of 5% 
trichloroacetic acid and water. Radioactivity was quantitated using a liquid scintil- 
lation spectrometer. Cultures labeled with [32p]Pi were incubated with 1 N NaOH 
for 2 h at 37°C prior to harvesting to hydrolyze RNA. 
Separation of cellular DNA and RNA by isopycnic centrifugation in Cs2S04 
The method for Cs2SO4 isopycnic centrifugation was a modification of the pro- 
cedure described by Stenberg et al. (1988). [32P]Pi at a final concentration of 3 
/.tCi/ml was added to untreated and drug-treated KB cell monolayers to label cellu- 
lar DNA and RNA. Following an incubation period of 24 h, ceils were harvested 
by adding 0.25 M EDTA (pH=8.0) and the cell suspensions were centrifuged at 
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low speed for 5 min at 5°C. The resulting pellets were stored at -20°C until further 
analysis. The pellets were thawed, suspended in 1.2 ml of TES buffer (30 mM Tris, 
5 mM EDTA, 50 mM NaC1, pH=8.0) and vortexed. Subsequent isolation of nucleic 
acids was accomplished by adding 1.2 ml of a solution of pronase (4 mg/ml) in 
TES buffer containing 2% sarkosyl to the pellet suspension and incubating for 20 
min at 37°C. One ml of the resulting suspension was mixed with 9 ml of 1.93 M 
Cs2SO4 in TES buffer (0.8 g/ml) and centrifuged at 120 000 x g for 66 h at 15°C in 
a Beckman L3-50 ultracentrifuge using a Ti 70.1 rotor. Samples were collected 
from the bottom of the centrifuge tubes and 50 fll of each fraction was transferred 
to a well of a 96-well tissue culture plate. The contents of each well were treated 
with 5% trichloroacetic acid and then collected onto filter paper using the Skatron 
cell harvester. The radioactivity of acid-precipitable materials was determined as 
detailed above. 
Cell growth rates 
The growth rates of uninfected KB and HFF cells were determined as described 
by Nassiri et al., 1990. Population doubling times were calculated using numbers 
of cells obtained at 24 and 96 h after planting. 
Plating efficiency 
An additional assay, plating efficiency, was used to confirm and extend results 
from cell growth experiments. KB and HFF cells were suspended in growth 
medium and an aliquot containing 500-600 cells was added to a 140 x 25 mm petri 
dish. Growth medium (40 ml) containing selected concentrations of test com- 
pounds was added and the cultures were incubated in a humidified atmosphere of 
4% CO2-96% air at 37°(2 for 14 days. Medium was decanted and attached cells 
were fixed with methanol and stained with 0.1% crystal violet in 20% methanol. 
Macroscopic colonies >1 mm in diameter were enumerated. 
Flow cytometry 
Cultures of KB cells as well as HFF cells were incubated with or without com- 
pound 102. Cell cycle analysis by flow cytometry was accomplished on a EPICS V 
flow cytometer (Coulter Electronics, Miami, FL) fitted with an argon-ion laser 
emitting at 488 nm (400 mW), a 515-nm long pass filter, 560-nm dichroic filter and 
630-nm long pass filter. A minimum of 10 000 cells were analyzed for each histo- 
gram generated. Details of the methods have been described earlier (Nassiri et al., 
1990). 
Data analysis 
Dose-response relationships were used to compare drug effects. These were con- 
structed by linearly regressing the percent inhibition of parameters derived in the 
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preceding sections against log drug concentrations. The 50% inhibitory 05o) con- 
centrations were calculated from the regression lines using the methods described 
by Goldstein (1964). Dose-response relationships for DNA histograms were evalu- 
ated by methods described previously (Drach et al., 1981). Briefly, the total area 
under the histogram was quantitated and normalized for the number of cells present 
in each culture. 
Results 
Activity against HCMV 
The antiviral activity of the acyclic halogenated tubercidin analogs previously 
described by us as compounds 10, 11, and 12, but referred to herein as compounds 
100, 102 and 104 (Fig. 1), was initially discovered using plaque-reduction assays 
(Pudlo et al., 1988). Those results showed the compounds were active against 
HCMV in the micromolar range 05o = 16, 3.9 and 24/tM, respectively). In order to 
more completely define activity against HCMV, yield (titer) reduction experiments 
were employed in the current study. Fig. 2 displays results of such experiments and 
compares the activities of the three compounds to that of acyclovir, a known antivi- 
ral nucleoside with the same acyclic sugar. In agreement with our previous results 
(Pudlo et al., 1988) the acyclic bromotubercidin analog (compound 102) was the 
most potent of the four agents tested against HCMV. At a concentration of 100 
/~M, compound 102 reduced the virus titer well below 1% of control. Compound 
104 was approximately 5-fold less potent at this concentration whereas compound 
100 and acyclovir were almost 50 times less potent than compound 102. None of 
the compounds tested, however, was as potent as ganciclovir - -  another clinically 
useful antiviral compound possessing a different acyclic sugar. Virus titers were 
reduced 105-fold by 32 ¢tM ganciclovir (data not shown). 
1 0 0 0  " 
A c y c l o v i r  
r-- 1" 
> 
C o m p o u n d  1 0 4  ~ ~ m  
"1"  
0 1  . . . . . . . .  , . . . . . . . .  , . . . . . . . .  , . . . . .  
1 1 0  1 0 0  1 0 0 0  
DRUG CONCENTRATION (gM) 
Fig. 2. Effects of acyclic halogenated tuhercidin analogs on the replication of HCMV. Subconfluent mono- 
layers of HFF cells were infected with 0.5 PFU per cell of HCMV and incubated in the presence of test 
compounds for 7 days. Infectious virus was quantitated by plaque assay. Control titers ranged 2.7 x 10 4 to 
5.2 x |0  ~ PFU per ml. 
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Inhibition of viral DNA synthesis 
The three acyclic nucleosides and ganciclovir were examined for their inhibitory 
effect on viral DNA synthesis in HCMV-infected cells by means of DNA-DNA dot 
blot hybridization. The results are shown in part A of Table 1. The potency of inhi- 
bition of HCMV DNA synthesis by the acyclic compounds was in the same rank 
order as seen in both plaque and titer reduction assays, namely, the 5-Br analog > 
5-1 > 5-C1. Compound 102 was comparable in activity to ganciclovir in this assay. 
The 150 concentrations for viral DNA synthesis appeared to be slightly lower than 
150 concentrations obtained in plaque-reduction assays (Pudlo et al., 1988) suggest- 
ing inhibition of viral DNA synthesis is causally related to antiviral activity. 
Effects on labeled precursor incorporation in uninfected cells 
When the inhibitory effects of the three acyclic compounds on uninfected cells 
were measured by visual inspection as part of plaque-reduction assays, compounds 
100, 102, and 104 produced virtually no cytopathogenic effects at 100/.tM (Pudlo 
et al., 1988). In contrast, when the effects of the compounds were measured by the 
uptake of labeled precursors, inhibition was noted. Parts B and C of Table 1 show 
that all three compounds but not ganciclovir inhibited cellular DNA synthesis 
(measured by [3H]dThd uptake) in both KB and HFF cells. The Is0 concentrations 
ranged from 0.38 to 2.9 pM in KB cells and 0.09 to 3.4/.tM in HFF cells. In con- 
TABLE 1 
Effect of acyclic halogenated tubercidin analogs on HCMV DNA synthesis and labeled precursor incor- 
poration in uninfected cells a 
Precursor 150 concentration (tiM) for compound 
100 102 104 Ganciclovir 
A. H C M V  
DNA Synthesis 4.3 1.6 4.6 1.8 
B. KB Cells 
[3H]dThd 1.1 0.38 2.9 354 
[3H]Urd 284 771 > 100 b > 1000 
3H-amino acids 502 626 > 100 > 1000 
[3Zp]Pi 30 11 65 591 
C. HFF Cells 
[3H]Thd 0.09 0.09 3.4 ND c 
[3H]Urd 139 150 80 ND 
3H-amino acids 151 365 239 ND 
a Incorporation of labeled precursors into acid-precipitable material in uninfected cells was determined as 
described in the text. HCMV D N A  synthesis was measured by D N A - D N A  hybridization. Each 150 concen- 
tration was determined from a dose-response curve constructed using data from at least two seperate exper- 
iments. 
b > indicates 150 concentration was not reached at highest (noted) concentration tested. 
c ND, not determined. 
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trast, the use of [32p]Pi to label DNA revealed less inhibition than was observed by 
labeling with [3H]dThd. Differences of 22- to 30-fold were noted for the three 
acyclic compounds but less than a two-fold difference was observed with ganciclo- 
vir. None of the compounds exhibited significant inhibitory effects on the incor- 
poration of [3H]Urd into RNA or 3H-amino acids into protein. 
To confirm the results of [3H]Urd labeling and to ensure that the procedure for 
labeling with [32p]Pi and subsequent hydrolysis of RNA had labeled only DNA, 
32p-labeled RNA and DNA isolated from drug-treated cultures were separated on 
Cs2SO4 gradients. Fig. 3 shows the Cs2SO4 isopycnic profiles of nucleic acids from 
untreated KB cells and cells treated with 10 aM of compound 102. As seen from 
the profiles, the amount of radioactivity incorporated into RNA was equal in both 
untreated and treated cells, showing no inhibition of RNA synthesis occurred. In 
contrast, the amount of radioactivity incorporated into DNA in treated cultures sug- 
gested nearly a 45% reduction in cellular DNA synthesis. At concentrations of 3.2 
and 32 aM of the same compound, 33% and 83% reductions in the synthesis of 
DNA were noted respectively (profiles not shown). At 32 aM, a 48% reduction in 
RNA synthesis occurred. 
Dose-response relationships for the inhibition of DNA synthesis were con- 
structed from the Cs2SO4 gradient profiles and an I50 concentration of 7.2 aM was 
interpolated. This value is consistent with that obtained by 32p-labeling and hydro- 
lysis (11 aM, Table 1 ) but is inconsistent with that attained by [3H]dThd incorpora- 
tion (0.38 aM). 
Flow cytometry 
Because of the different results obtained by incorporation of [3H]dThd and 
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Fig. 3. Effect of compound 102 on incorporation of [32P]H3PO4 into RNA and DNA of KB cells. Cultures 
of KB cells were labeled with 3/tCi/ml [32p]Pi and treated with(C))or without (O)10 ,uM compound 102. 
Following a 24-h incubation, cells were harvested and nucleic acids separated by isopycnic centrifugation 
in Cs2SO4 gradients. 
143 
uninfected KB cells by measuring fluorescence from intercalated propidium diiod- 
ide using a flow cytometer. DNA histograms comparing untreated cultures and cul- 
tures treated with 10/IM compound 102 are presented in Fig. 4. Results show that 
drug-treated cultures exhibit the following: a marked decrease of cells in the G0/G1 
phase of the cell cycle, a marked accumulation of cells in mid-S phase, and a dimi- 
nished population of cells in the G2/M population fraction. Similar results were 
obtained with HFF cells (data not shown). 
Similar experiments were performed with other concentrations of compound 102 
to construct a dose-response relationship for the effect on total DNA content as 
measured by propidium diiodide fluorescence. An 150 concentration of approxi- 
mately 0.9 ¢tM was obtained. This measurement agrees more closely with the 
results of [3H]dThd incorporation than of [32p]Pi incorporation. 
Cell growth and population doubling time 
Because DNA histograms showed definite S-phase blockage of DNA synthesis 
the effects of compounds on suppression of cell growth in uninfected KB and HFF 
cells were investigated. Growth curves were generated in the presence and absence 
of test compounds. During a typical 70-h incubation, untreated KB cells underwent 
three population doublings. Concentrations up to 10/AVI compound 104 and 100 
¢tM compound 100 only slightly increased the doubling time of KB cells to 27-30 
h (Table 2). Compound 102 was significantly more potent. A 10-¢tM concentration 
of compound 102 caused a pronounced prolongation of cell doubling time to 84 h. 
The effect of these compounds on HFF cells was slightly less pronounced than 
their effect on KB cells (data not shown). 
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Fig. 4. DNA histograms illustrating nonparametric comparisons of untreated KB cells and KB cells treated 
for 24 h with 10/.tM compound 102 and then analyzed by flow cytometry. Each histogram is the average of 
five individual cultures. Peaks 1 and 2 represent nuclei from chicken erythrocytes and human lymphocytes, 
respectively. The inserted time line details the stages of the cell growth cycle which correspond to seg- 
ments of the control DNA histogram. 
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TABLE 2 




PDT (h) in the presence of compound 
100 102 104 
0 23 23 23 
0.1 ND" 30 26 
1 25 43 25 
10 25 84 30 
100 27 ND ND 
a ND, not determined. 
Plating efficiencies 
The effects of the acyclic compounds on the attachment and colony formation of 
KB and HFF cells were determined as a more stringent measure of their effects on 
uninfected cells. The results of plating efficiency assays are presented in Table 3 as 
150 concentrations. Included in the comparison is compound 080 which is the parent 
compound of the series, unsubstituted in the 5-position. This compound is inactive 
against HCMV and is non-cytotoxic in other assays (Saxena et al., 1988). In the 
current study it also did not affect the plating and growth of KB cells (Table 3). In 
contrast, the halogenated analogs inhibited the capacity of KB cells to attach and 
form colonies at concentrations similar to those which inhibit [3H]dThd incorpora- 
tion (see Table 1). Surprisingly, ganciclovir was inhibitory in this assay at concen- 
trations 10-fold less than those required to inhibit labeled precursor incorporation 
(Table 1). All compounds, including compound 080 and ganciclovir, had more pro- 
nounced effects on HFF cells than KB cells. The marked effect of compound 080 
showed that HFF cells are particularly sensitive to the pyrrolopyrimidine nucleo- 
sides. This probably is due in part to the lower cloning efficiency of  HFF cells com- 
pared to KB cells. 
TABLE 3 
Effect of acyclic tubercidin analogs on relative plating efficiencies 
Compound 150 concentration (tiM) 
KB cells HFF cells 
080 > 320 a 18 
100 3.9 0.17 
102 0.25 0.08 
104 1.2 0.11 
Ganciclovir 51 35 
" Less than 20% inhibition observed at highest concentration tested (320 tiM). 
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TABLE 4 
Adenosine antagonism of the effect of acyclic halogenated tubercidin analogs on [3H]thymidine incorpora- 
tion by KB cells a 
Compound Adenosine Is0 
concentration (tiM) concentration (tiM) 
100 0 0.74 
3.2 1.7 
10 2.9 
32 > l0 b 




a Incorporation of [3H]Thd was performed as described in the text except that 1/zg/ml of deoxycoformycin 
was added to prevent the deamination of adenosine. Protocols for determining I50 concentrations in the 
presence and absence of adenosine and deoxycoformycin have been detailed elsewhere (Birch et al., 1989). 
Data are from three separate experiments. 
b 150 concentration was not reached at highest concentration (10/zM) tested. 
Antagonism of effects on [3H]thymidine incorporation by adenosine 
Previous studies by us (Birch et al., 1989) have shown that the effect of sangiva- 
mycin [a pyrrolopyrimidine nucleoside phosphorylated by adenosine kinase 
(Suhadolnik, 1979)] on [3H]dThd incorporation by uninfected cells is antagonized 
by adenosine. To explore if effects of the acyclic halogenated tubercidin analogs 
on [3H]dThd incorporation by KB cells also might be mediated by adenosine kin- 
ase, similar studies with compounds 100 and 102 were performed. Dose-response 
relationships for inhibition of [3H]dThd incorporation by the two compounds were 
examined at selected concentrations of adenosine. All concentrations of adenosine 
from 3.2 to 50 pM caused dose-response curves to shift to the right (data not 
shown). Table 4 presents 150 concentrations from these curves and establishes that 
the activity of both compounds was antagonized by adenosine. These data suggest 
that antagonism may have occurred at the kinase level. 
Discussion 
Our initial testing of acyclic halogenated pyrrolo[2,3-d]pyrimidines showed 
these compounds were active against HCMV and herpes simplex virus (HSV) type 
1 and did not produce visual cytotoxicity in uninfected cells (Pudlo et al., 1988). 
Subsequent studies (Nassiri et al., 1990) showed, however, that compound 102 
inhibited cell growth but did so in a reversible, cytostatic manner. Thus, no visual 
cytotoxicity was noted earlier (Pudlo et al., 1988) because cell death had not 
occurred even though cell division was blocked. 
The current study was initiated to explore cellular and molecular mechanisms by 
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which compound 102 and two closely related analogs produce antiviral and 
cytostatic activity, Based upon results presented in this report, the biochemical 
actions of the acyclic halogenated pyrrolopyrimidines appear to be more restricted 
than the actions of the parent naturally-occurring nucleosides tubercidin, toyoca- 
mycin, and sangivamycin (Suhadolnik, 1979; Ritch and Glazer, 1984). These 
ribosyl pyrrolopyrimidines inhibit virus replication but are highly cytotoxic as well 
(Turk et al., 1987b). Results with all three acyclic halogenated compounds, but 
especially results with compound 102, clearly demonstrate inhibition of both cellu- 
lar and viral DNA synthesis as primary events. Even though Yang et al. (1990) 
found evidence for inhibition of protein synthesis in guinea pig CMV-infected cells 
at high concentrations (800 tiM) of compound 102, we found little or no inhibition 
of RNA or protein synthesis at concentrations (up to 100 ~M) which gave good 
activity against HCMV. These short-term studies (24 h), however, were not 
designed to be fully indicative of potential secondary effects accumulating during 
long-term exposure to the compounds. 
The questions of whether inhibition of DNA synthesis is sufficient to account 
entirely for antiviral activity and whether preferential inhibition of viral DNA syn- 
thesis occurs are still not fully answered. Data favoring the interpretation that the 
compounds have antiviral selectivity include the observation that viral DNA syn- 
thesis was inhibited by drug concentrations approximately 10-fold lower than 
required for inhibition of cellular DNA synthesis as measured by [32p]Pi incorpora- 
tion (Table 1 and Fig. 3). In addition, concentrations of compounds 102 and 104 
(e.g. 10/AVI) which inhibited HCMV replication by >95% (Fig. 2) produced only 
slight (compound 104) or 3-fold (compound 102) increases in population doubling 
times of uninfected cells (Table 2). Further evidence for viral specificity are data 
by Hu and Hsiung (1989a) which show a marked multiplicity of infection effect for 
the activity of compound 102 against guinea pig lymphotropic herpesvirus 
(GPHLV). Arguing against the theory of antiviral selectivity are data obtained by 
[3H]dThd incorporation (Table 1), flow cytometry (Fig. 4) and plating efficiency 
(Table 3). Cellular DNA synthesis as measured by these two means and plating 
efficiency were more sensitive to inhibition by the compounds than was viral DNA 
synthesis. 
Clearly, more investigation is needed to reconcile these disparate results. The 
lack of agreement of the isotopic methods for quantitating DNA synthesis is par- 
ticularly puzzling. Previously we had observed a similar phenomenon with ribavi- 
rin wherein [3H]dThd incorporation was more sensitive to inhibition than was 
[32p]Pi incorporation (Drach et al., 1981). In that case, however, results from flow 
cytometry correlated better with the [32p]Pi data than the [3H]dThd results. It was 
discovered that [3H]dThd incorporation greatly overestimated inhibition of DNA 
synthesis due to drug-induced perturbations in labeled thymidine nucleotide pools. 
A similar explanation does not appear to apply in the present case and it is difficult 
to envision a mechanism whereby these compounds could increase the specific 
activity of the [32p]-labeled dNTP pools and effect an overestimation of inhibition 
of DNA replication. 
Enzymatic mechanisms by which these compounds act have not been explored 
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directly. Our data and that of others do, nonetheless, suggest biochemical bases for 
the action and possible antiviral selectivity of the compounds. Based on the facts 
that DNA but not RNA or protein synthesis is inhibited and that related nucleoside 
analogs such as acyclovir must be phosphorylated to inhibit DNA synthesis 
(Drach, 1984), we assume that the acyclic compounds also must be phosphory- 
lated. For the reasons that HCMV does not encode any currently known nucleoside 
kinases (Kit, 1979), the activity of compound 102 against HSV type 1 is cell-line 
dependent (Hu and Hsiung, 1989b) and the inhibition of [3H]dThd incorporation by 
uninfected cells is antagonized by adenosine (Table 4), we speculate that this com- 
pound is activated by cellular adenosine kinase. Despite the possibility that 
HCMV-encoded nucleoside kinases may not exist, it has been demonstrated that 
cellular nucleoside kinases are stimulated during HCMV infection (Estes and 
Huang, 1977; Freitos et al., 1985). This could lead to preferential phosphorylation 
of the acyclic halogenated tubercidin analogs by virus-infected cells and confer 
some degree of antiviral specificity. 
The site of action of putative nucleoside phosphates is even more speculative. 
Labeled precursor incorporation, DNA-DNA hybridization and flow cytometry 
data all show inhibition of DNA synthesis. The most logical loci of inhibition are 
DNA polymerase and ribonucleotide reductase. Indeed, the 5 -triphosphate of the 
arabinosyl analog of tubercidin is an inhibitor of cellular and HSV-encoded DNA 
polymerases (Turk et al., 1987a) as well as HCMV-encoded DNA polymerase (our 
unpublished data). Furthermore, the need to keep compound 102 in contact with 
cells for it to express antiviral (Yang et al., 1990) and cytostatic activity (Nassiri et 
a1.,1990) plus the fact that these activities are reversed by drug removal, suggest 
the following: incorporation into DNA and blockage of chain elongation are not 
likely mechanisms of DNA synthesis inhibition or incorporated molecules are read- 
ily removed from DNA by repair mechanisms. 
The 5'-diphosphates of tubercidin and toyocamycin have been reported to be 
substrates (and therefore potential inhibitors) of ribonucleotide reductase derived 
from E. coli (Chassey and Suhadolnik, 1968). The accumulation of cells in mid S- 
phase by compound 102 is similar to results seen when cells are treated with high 
concentrations of dThd (our unpublished results), a condition wherein reductase is 
inhibited via feedback regulation by dTTP (Nutter and Cheng, 1984). In contrast, 
cells treated with hydroxyurea (a more potent inhibitor of ribonucleotide reductase) 
accumulate at the G~/S border (Bhuyan and Groppi, 1989), suggesting that com- 
pound 102 is not an exceptionally potent inhibitor of ribonucleotide reductase. 
Firm data to resolve possibilities such as these await enzymatic studies to more 
fully understand the mode-of-action of these novel compounds. 
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